OMRON Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) to market new home blood pressure monitors featuring AI-powered atrial fibrillation ...
In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug ...
The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback